COMPANY
Company Identity
COMPANY
Company Identity
LEADING GLOBAL R&D Innovator
CURACLE Co., Ltd. presents a healthy and happy life by developing innovative global
new drugs for intractable vascular diseases.
Embarking on a New Challenge, Miracle Cure, Leading Global Market
Present
Unmet Medical Needs
• Diabetic Macular Edema(DME)
• Wet Macular Degeneration
• Inflammatory Bowel Disease(Ulcerative Colitis, Crohn’s Disease)
• Cancer
• Diabetic Nephropathy
• Ischemic Vascular Diseases
• Stroke
• Kidney Failure
• Dementia, etc.
Key Development
Age-Related Vascular Diseases
Intractable Metabolic Diseases
Targeted Therapy / Immunotherapy for Cancer
Future
Creative Scientific Discovery
Innovative Molecules
New Clinical Concept
• Vascular Normalization
• Inhibition of Abnormal Angiogenesis
• Suppression of Inflammation
Novel Therapeutics
Leading rapidly growing present and future market
Global enterprise growth by developing unparalleled platform technology and creating innovative new drugs
Strengthening market leadership through the continued success of pipelines and global partnerships
Growth stage
(-2020)
• Portfolio consisting of drug candidates and early phase clinical trials
• Completed Phase 2a clinical trial of CU01 & CU03
• Entered Phase 1 clinical trial of CU06
• Completed Series B financing
• Build relationship with domestic and foreign partners
• Completed technology assessment for special listings
Take-off Stage
(2021-2025)
• Add new innovative pipeline
• Initial Public Offering (IPO)
• Portfolio consisting of pre-clinical and late phase clinical trials
• Out-licensing and co-development with domestic and international pharmaceutical companies
• Creation of milestone profits
• Laboratory integration
• Addition of new innovative pipelines
Achieving VISION
(2026-)
• Establish unrivaled and innovative drug platform
• Launch internally developed drugs worldwide
• Global R&D innovator leader focused
on unmet medical needs